E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

doi:10.1158/2159-8290.CD-17-0603

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Cancer discovery - 1 Apr 2018

Bajrami Ilirjana, Marlow Rebecca, van de Ven Marieke, Brough Rachel, Pemberton Helen N, Frankum Jessica, Song Feifei, Rafiq Rumana, Konde Asha, Krastev Dragomir B, Menon Malini, Campbell James, Gulati Aditi, Kumar Rahul, Pettitt Stephen J, Gurden Mark D, Cardenosa Marta Llorca, Chong Irene, Gazinska Patrycja, Wallberg Fredrik, Sawyer Elinor J, Martin Lesley-Ann, Dowsett Mitch, Linardopoulos Spiros, Natrajan Rachael, Ryan Colm J, Derksen Patrick W B, Jonkers Jos, Tutt Andrew N J, Ashworth Alan, Lord Christopher J

Abstract excerpt

The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered CDH1 mutations, we identified synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1. Data from large-scale genetic screens in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD

Share to Cadherins

Share to Crizotinib

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Quinolines

Source

Open in PubMed Open full text

Identifiers

PMID: 29610289
DOI: 10.1158/2159-8290.CD-17-0603
PMCID: PMC6296442

Genes

ROS1
CDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.PMID 29610289Read ↗

<i>CDH1</i> loss remodels gene expression and lineage identity in human mammary epithelial cellsSemantic proximity Read ↗

E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.Semantic proximity Read ↗

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic LethalitySemantic proximity Read ↗

Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen.Semantic proximity Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

CRISPR/Cas9 Targeting of Aldehyde Dehydrogenase 1A1 Reveals Heterogeneous Roles in Radiation Response and Redox Stress Across Clonal Lines in Triple-Negative Breast CancerSemantic proximity Read ↗

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancersSemantic proximity Read ↗

Functional viability profiles of breast cancer.Semantic proximity Read ↗

Loss of E-cadherin Induces IGF1R Activation Revealing a Targetable Pathway in Invasive Lobular Breast CarcinomaSemantic proximity Read ↗

Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells.Semantic proximity Read ↗

CRISPR Double Knockout Library Reveals Synthetic Lethal Gene Pairs in Triple-Negative Breast CancerSemantic proximity Read ↗

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.